Merck, known as MSD outside the US and Canada, makes the cancer drug Keytruda, the Gardasil vaccine and animal medicines. Keytruda brought in $8.6 billion of its $18.1 billion of sales in the third quarter of 2026, and its main US patents begin to expire in 2028.
Biggest ties:Alteogen (enzyme for Keytruda Qlex); Moderna (cancer treatment partner); Cancer patients (Keytruda and other cancer drugs)
The map
Suppliers sit above Merck, customers below. Tap a box, or step through with the arrows.
Keytruda Qlex, the version given as a shot under the skin, combines Keytruda with an enzyme licensed from Alteogen, a South Korean company. Qlex sold $830 million in the third quarter of 2026.
What to watch: How many patients move to Qlex before 2028.
Boxes with a corner arrow have their own map. Sizes show where a source gives one.
Outside forces
Things Merck can't control that affect its business. Tap one to see what to watch.
Keytruda patentsKeytruda and Qlex brought in about $31.7 billion in 2025, nearly half of Merck's sales. Key US patents on its active ingredient begin to expire in 2028, and Merck expects copies to affect sales materially from 2028 to 2029.What to watch
Buying new drugsMerck's 2026 outlook includes one-time charges of $6.05 a share for deals, mostly Cidara and Terns. It also bought Verona Pharma for about $10 billion in 2025, adding the lung drug Ohtuvayre, which sold $184 million in the third quarter.What to watch
Key US patents begin to expire in 2028. Merck expects copies to affect sales materially in 2028 to 2029.
What is Keytruda Qlex?
A version of Keytruda given as a quick shot under the skin instead of a drip. It uses an enzyme licensed from Alteogen and sold $830 million in the third quarter of 2026.
Why is Merck called MSD?
Merck & Co. uses the name MSD outside the US and Canada.
Read every connection
All 10 connections as cards, with sources. It's the same detail you get by tapping a box on the map.Show allHide
Suppliers
The companies Merck relies on to make what it sells, with sources.
Alteogen
Enzyme for Keytruda Qlex
Size$830 million of Qlex sales (Q3 2026)
Keytruda Qlex, the version given as a shot under the skin, combines Keytruda with an enzyme licensed from Alteogen, a South Korean company. Qlex sold $830 million in the third quarter of 2026.
What to watch: How many patients move to Qlex before 2028.
Merck bought Cidara for about $9.2 billion in January 2026 for CD388, a long-acting drug in late-stage testing to prevent flu in people at higher risk. It was booked as a $9.0 billion research charge.
Gardasil sold $2.0 billion in the third quarter of 2026, up from $1.75 billion. Capvaxive sold $263 million, while Vaxneuvance fell 14% on lower US government buying.
Connections were last checked against company filings and news reports on Nov 21, 2026. Companies don't have to disclose every supplier or customer, so this map shows the most important ones that are publicly known, not every link.
How we check connections. StockTies is for information only. It is not investment advice. Spot something out of date? Tell us.